Logo image
Back
Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression
Journal article   Open access   Peer reviewed

Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression

Chiara C Bortolasci, Srisaiyini Kidnapillai, Briana Spolding, Trang T.T. Truong, Timothy Connor, Courtney Swinton, Bruna Panizzutti, Zoe S.J. Liu, Andrew Sanigorski, Olivia M. Dean, …
Bipolar disorders, Vol.25(8), pp.661-670
12/2023
DOI: https://doi.org/10.1111/bdi.13319
PMID: 36890661
pdf
Use of a gene expression signature1.70 MBDownloadView
Published (Version of record) Open Access CC BY V4.0
url
Use of a gene expression signatureView
Published (Version of record) Open CC BY V4.0

Related links

Metrics

6 Record Views
11 Times Cited - Web of Science

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Abstract

bipolar depression drug repurposing gene expression signature trimetazidine
Objectives: The aim of this study was to repurpose a drug for the treatment of bipolar depression. Methods: A gene expression signature representing the overall transcriptomic effects of a cocktail of drugs widely prescribed to treat bipolar disorder was generated using human neuronal-like (NT2-N) cells. A compound library of 960 approved, off-patent drugs were then screened to identify those drugs that affect transcription most similarly to the effects of the bipolar depression drug cocktail. For mechanistic studies, peripheral blood mononuclear cells were obtained from a healthy subject and reprogrammed into induced pluripotent stem cells, which were then differentiated into co-cultured neurons and astrocytes. Efficacy studies were conducted in two animal models of depressive-like behaviours (Flinders Sensitive Line rats and social isolation with chronic restraint stress rats). Results: The screen identified trimetazidine as a potential drug for repurposing. Trimetazidine alters metabolic processes to increase ATP production, which is thought to be deficient in bipolar depression. We showed that trimetazidine increased mitochondrial respiration in cultured human neuronal-like cells. Transcriptomic analysis in induced pluripotent stem cell-derived neuron/astrocyte co-cultures suggested additional mechanisms of action via the focal adhesion and MAPK signalling pathways. In two different rodent models of depressive-like behaviours, trimetazidine exhibited antidepressant-like activity with reduced anhedonia and reduced immobility in the forced swim test. Conclusion: Collectively our data support the repurposing of trimetazidine for the treatment of bipolar depression.

Details

Logo image